Classic CIDP Typically Presents with Distal and Proximal Symptoms
Classic Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) typically presents with both distal and proximal symptoms, rather than exclusively distal symptoms. 1
Clinical Presentation of Classic CIDP
- Classic CIDP is characterized by a symmetrical, motor-predominant peripheral neuropathy that produces both distal and proximal weakness 1
- Large-fiber abnormalities (weakness and ataxia) predominate in classic CIDP, while small-fiber abnormalities (autonomic dysfunction and pain) are less common 1
- The hallmark of classic CIDP is the involvement of both proximal and distal muscles with globally diminished or absent reflexes 2
Distinguishing Classic CIDP from Atypical Variants
While classic CIDP involves both proximal and distal segments symmetrically, there are several atypical variants with different presentation patterns 3:
The pathophysiology of these variants may differ:
Diagnostic Considerations
- Electrophysiological studies in classic CIDP show slowed conduction velocities, temporal dispersion, and conduction block 1
- Cerebrospinal fluid analysis typically reveals elevated protein with normal cell count (cytoalbuminologic dissociation) 5
- Nerve biopsy in classic CIDP shows segmental demyelination, onion-bulb formation, and endoneurial inflammatory infiltrates 1
- MRI of the brachial or lumbosacral plexus may help identify focal or diffuse peripheral nerve abnormalities 5
Differential Diagnosis
- Polyneuropathy typically begins distally and progresses proximally in a length-dependent pattern, with symptoms usually beginning symmetrically in the toes and feet 6
- In contrast, classic CIDP involves both proximal and distal segments from earlier in the disease course 1
- Other conditions to consider in the differential diagnosis include:
Treatment Approach
- Early treatment of CIDP is crucial and should be guided by evidence-based therapies 7
- First-line treatments include:
- For severe or progressing symptoms, consider pulse corticosteroids (methylprednisolone 1g IV daily for 3-5 days) plus IVIG 2g/kg over 5 days 5
- Treatment response should be judged by objective measures (improvement in neurological or electrophysiological examination) 1
Clinical Pitfalls and Caveats
- Pain is unusual in classic CIDP; prominent pain may suggest other diagnoses or atypical variants 2
- Atypical presentations may require nerve biopsy for definitive diagnosis 5
- There is no reliable disease activity biomarker for CIDP, making treatment optimization challenging 7
- Serial clinical assessments are key to understanding the value of continued immunotherapy 7